TTRX

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)

EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)

POS AM - Turn Therapeutics Inc. (0002023016) (Filer)

POS AM - Turn Therapeutics Inc. (0002023016) (Filer)

10-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Phase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026 Secured up to $25 Million in Growth Capital from Avenue Capital Group Strengthened Leadership Team via Appointments of Dr. Robert Redfield and Martin Dewhurst Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results for the year ended December 31, 2025, and provided corporate updates. "Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities," said Bradley

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Financing Extends Runway and Supports Continued Advancement of Atopic Dermatitis (Eczema) and Onychomycosis (Nail Fungus) Programs Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, for up to $25 million. The facility includes an initial $7 million tranche funded at closing, with up to an additional $18 million available upon achievement of clinical and corporate milestones. "This financing comes at a critical inflection point for Turn as we approach the mid-

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company's lead investigational therapy Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company's lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials. This

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference. The Company will provide an update on its dermatology pipeline, including the status of the ongoing Phase 2 clinical trial evaluating GX-03, the company's lead investigational therapy for moderate-to-severe atopic dermatitis (eczema). Management will also participate in one-on-one meetings with institutional investors. Conference Participation: 36

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

3 - Turn Therapeutics Inc. (0002023016) (Issuer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office

D. Boral Capital initiated coverage of Turn Therapeutics with a rating of Buy and set a new price target of $8.00

4 - Turn Therapeutics Inc. (0002023016) (Issuer)